Telomir Pharmaceuticals has submitted an investigational new drug application to the US Food and Drug Administration for Telomir-1 (Telomir-Zn), its lead candidate targeting advanced and metastatic triple-negative breast cancer (TNBC).
The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Pending IND clearance, Telomir Pharmaceuticals aims to start a Phase I/II clinical trial of Telomir-1 as an oral single agent for patients with advanced or metastatic TNBC.
Telomir-Zn is described as a first-in-class metal-modulating epigenetic agent designed to restore transcriptional control in tumour cells.
According to to a company release, Telomir said that IND-enabling good laboratory practice (GLP) safety studies reported no treatment-related or dose-limiting toxicities and favourable cardiovascular, respiratory, and phototoxicity profiles. Systemic exposure was consistent, and pharmacokinetics were predictable.
The Phase I segment of the trial will use a standard three-plus-three dose-escalation design to evaluate the safety, tolerability, dose-limiting toxicities, and recommended Phase II dose.
Phase II will use a Simon two-stage design to assess preliminary antitumour activity through objective response rate as the primary endpoint, along with duration of response, progression-free survival, and continued safety evaluation.
Telomir Pharmaceuticals has submitted manuscripts to peer-reviewed journals and plans to present its findings at scientific conferences, including the American Association for Cancer Research (AACR) annual meeting in 2026.
Telomir Pharmaceuticals CEO Erez Aminov said: “This IND submission marks a critical transition from preclinical proof-of-concept to clinical development for Telomir-Zn.
“TNBC patients with advanced disease have few durable treatment options, and we believe that targeting the biological mechanisms driving treatment resistance, specifically iron-dependent epigenetic dysregulation, represents a differentiated and scientifically grounded approach. We look forward to advancing this programme into the clinic.”
